source
- Eli Lilly's $3.8 B acquisition of AtaiBeckley signals growing confidence in psychedelics for depressionPsychedelics are being touted as a potential solution for patients who still struggle to find lasting relief from existing FDA‑approved psychiatric medicines. The article notes that many individual…
- FDA advisory panel set to review Grail’s multi-cancer Galleri screening testAn FDA advisory committee is scheduled to evaluate Grail’s Galleri blood test, which is designed to detect a range of cancers at an early stage. The panel will examine the test’s clinical data, pe…